Short Interest in Avalon GloboCare Corp. (NASDAQ:CHGA) Drops By 69.7%

Avalon GloboCare Corp. (NASDAQ:CHGAGet Free Report) was the target of a significant drop in short interest in the month of August. As of August 31st, there was short interest totaling 68,808 shares, a drop of 69.7% from the August 15th total of 226,852 shares. Approximately 9.6% of the shares of the stock are sold short. Based on an average trading volume of 723,976 shares, the days-to-cover ratio is currently 0.1 days.

Avalon GloboCare Stock Performance

Shares of CHGA traded down $0.02 during midday trading on Friday, hitting $2.23. 21,781 shares of the company traded hands, compared to its average volume of 409,124. The firm has a 50 day moving average of $4.76 and a 200-day moving average of $7.92. Avalon GloboCare has a 52 week low of $2.15 and a 52 week high of $57.97. The stock has a market cap of $2.12 million, a price-to-earnings ratio of -0.16 and a beta of -0.05.

Avalon GloboCare (NASDAQ:CHGAGet Free Report) last issued its earnings results on Friday, August 14th. The company reported ($2.80) earnings per share (EPS) for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised Avalon GloboCare from a “sell (e)” rating to a “sell (e+)” rating in a research note on Monday, August 24th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Get Our Latest Research Report on CHGA

About Avalon GloboCare

(Get Free Report)

Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.

See Also

Receive News & Ratings for Avalon GloboCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalon GloboCare and related companies with MarketBeat.com's FREE daily email newsletter.